Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
80.00
+1.14 (1.45%)
At close: Mar 19, 2026, 4:00 PM EDT
81.00
+1.00 (1.25%)
After-hours: Mar 19, 2026, 6:51 PM EDT

Dianthus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4.0712.475.656.42-
Revenue Growth (YoY)
-67.35%120.63%-11.92%--
Gross Profit
4.0712.475.656.42-
Selling, General & Admin
34.3324.9918.166.7427.93
Research & Development
145.6483.1132.8429.3846.77
Total Operating Expenses
179.97108.15136.1274.69
Operating Income
-177.93-101.86-48.17-29.71-74.69
Interest Income
16.1217.374.761.15-
Other Non-Operating Income (Expense)
-0.52-0.47-0.150.083.56
Total Non-Operating Income (Expense)
15.616.94.621.233.56
Pretax Income
-162.34-84.97-43.56-28.48-71.14
Net Income
-162.34-84.97-43.56-28.48-71.14
Net Income to Common
-162.34-84.97-43.56-28.48-71.14
Shares Outstanding (Basic)
3933511
Shares Outstanding (Diluted)
3933511
Shares Change (YoY)
15.92%546.44%489.48%0.09%-68.18%
EPS (Basic)
-4.20-2.55-8.45-32.57-15.01
EPS (Diluted)
-4.20-2.55-8.45-32.57-15.01
Free Cash Flow
-129.27-78.29-36.97-29.21-60.8
Free Cash Flow Per Share
-3.35-2.35-7.17-33.41-69.60
Gross Margin
100.00%100.00%100.00%100.00%-
Operating Margin
-4369.67%-816.87%-852.34%-462.91%-
Profit Margin
-3986.67%-681.39%-770.61%-443.76%-
FCF Margin
-3174.68%-627.79%-654.12%-455.18%-
EBITDA
-177.82-101.77-48.11-29.68-72.67
EBITDA Margin
-4366.94%-816.10%-851.15%-462.44%-
EBIT
-177.93-101.86-48.17-29.71-74.69
EBIT Margin
-4369.67%-816.87%-852.34%-462.91%-
Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q